SK Biopharmaceuticals Licenses Biohaven’s Kv7 Platform in Deal Worth Up to $795 Million

SK Biopharm gains exclusive worldwide rights to Biohaven’s opakalim and Kv7 platform in a deal worth up to $795M, with a possible 2029 U.S. launch.